Molecular Partners Ag Stock Net Income
| MOLN Stock | CHF 3.57 0.05 1.42% |
As of the 6th of February, Molecular Partners secures the Mean Deviation of 3.06, risk adjusted performance of 0.0758, and Downside Deviation of 3.64. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Molecular Partners, as well as the relationship between them. Please verify Molecular Partners standard deviation, information ratio, treynor ratio, as well as the relationship between the variance and jensen alpha to decide if Molecular Partners AG is priced some-what accurately, providing market reflects its recent price of 3.57 per share.
Molecular Partners Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 3.8144 | Earnings Share (1.67) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -48.6 M | -46.2 M | |
| Net Loss | -48.6 M | -46.2 M | |
| Net Loss | -48.6 M | -46.2 M | |
| Net Loss | (1.83) | (1.73) | |
| Net Income Per E B T | 1.15 | 1.10 |
Molecular | Net Income |
The evolution of Net Income for Molecular Partners AG provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Molecular Partners compares to historical norms and industry peers.
Latest Molecular Partners' Net Income Growth Pattern
Below is the plot of the Net Income of Molecular Partners AG over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Molecular Partners financial statement analysis. It represents the amount of money remaining after all of Molecular Partners AG operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Molecular Partners' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Molecular Partners' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (54.04 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Molecular Net Income Regression Statistics
| Arithmetic Mean | (18,282,353) | |
| Geometric Mean | 17,904,344 | |
| Coefficient Of Variation | (242.19) | |
| Mean Deviation | 31,995,757 | |
| Median | (25,430,000) | |
| Standard Deviation | 44,278,440 | |
| Sample Variance | 1960.6T | |
| Range | 181.6M | |
| R-Value | (0.37) | |
| Mean Square Error | 1798.1T | |
| R-Squared | 0.14 | |
| Significance | 0.14 | |
| Slope | (3,283,112) | |
| Total Sum of Squares | 31369.3T |
Molecular Net Income History
Molecular Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Molecular Partners is extremely important. It helps to project a fair market value of Molecular Stock properly, considering its historical fundamentals such as Net Income. Since Molecular Partners' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Molecular Partners' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Molecular Partners' interrelated accounts and indicators.
Click cells to compare fundamentals
Molecular Partners 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Partners' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Partners.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Molecular Partners on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Molecular Partners AG or generate 0.0% return on investment in Molecular Partners over 90 days. Molecular Partners is related to or competes with Santhera Pharmaceuticals, Ascom Holding, Evolva Holding, S H, Newron Pharmaceuticals, and DocMorris. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and... More
Molecular Partners Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Partners' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Partners AG upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.64 | |||
| Information Ratio | 0.0791 | |||
| Maximum Drawdown | 22.81 | |||
| Value At Risk | (5.28) | |||
| Potential Upside | 7.56 |
Molecular Partners Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Partners' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Partners' standard deviation. In reality, there are many statistical measures that can use Molecular Partners historical prices to predict the future Molecular Partners' volatility.| Risk Adjusted Performance | 0.0758 | |||
| Jensen Alpha | 0.3476 | |||
| Total Risk Alpha | 0.1692 | |||
| Sortino Ratio | 0.0899 | |||
| Treynor Ratio | 0.8609 |
Molecular Partners February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0758 | |||
| Market Risk Adjusted Performance | 0.8709 | |||
| Mean Deviation | 3.06 | |||
| Semi Deviation | 3.31 | |||
| Downside Deviation | 3.64 | |||
| Coefficient Of Variation | 1111.62 | |||
| Standard Deviation | 4.14 | |||
| Variance | 17.13 | |||
| Information Ratio | 0.0791 | |||
| Jensen Alpha | 0.3476 | |||
| Total Risk Alpha | 0.1692 | |||
| Sortino Ratio | 0.0899 | |||
| Treynor Ratio | 0.8609 | |||
| Maximum Drawdown | 22.81 | |||
| Value At Risk | (5.28) | |||
| Potential Upside | 7.56 | |||
| Downside Variance | 13.24 | |||
| Semi Variance | 10.97 | |||
| Expected Short fall | (3.62) | |||
| Skewness | 0.6464 | |||
| Kurtosis | 2.05 |
Molecular Partners Backtested Returns
Molecular Partners appears to be unstable, given 3 months investment horizon. Molecular Partners has Sharpe Ratio of 0.0567, which conveys that the firm had a 0.0567 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Molecular Partners, which you can use to evaluate the volatility of the firm. Please exercise Molecular Partners' Risk Adjusted Performance of 0.0758, mean deviation of 3.06, and Downside Deviation of 3.64 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Molecular Partners holds a performance score of 4. The company secures a Beta (Market Risk) of 0.42, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Molecular Partners' returns are expected to increase less than the market. However, during the bear market, the loss of holding Molecular Partners is expected to be smaller as well. Please check Molecular Partners' total risk alpha, treynor ratio, and the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether Molecular Partners' current price movements will revert.
Auto-correlation | 0.24 |
Weak predictability
Molecular Partners AG has weak predictability. Overlapping area represents the amount of predictability between Molecular Partners time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Partners price movement. The serial correlation of 0.24 indicates that over 24.0% of current Molecular Partners price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.24 | |
| Spearman Rank Test | -0.52 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Molecular Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Molecular Partners AG reported net income of (54.04 Million). This is 115.84% lower than that of the Biotechnology sector and 177.15% lower than that of the Health Care industry. The net income for all Switzerland stocks is 109.46% higher than that of the company.
Molecular Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Partners' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Molecular Partners could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics of similar companies.Molecular Partners is currently under evaluation in net income category among its peers.
Molecular Fundamentals
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 29.78 M | ||||
| Shares Outstanding | 37.4 M | ||||
| Shares Owned By Insiders | 8.30 % | ||||
| Shares Owned By Institutions | 44.03 % | ||||
| Price To Earning | 2.02 X | ||||
| Price To Book | 1.34 X | ||||
| Price To Sales | 166.37 X | ||||
| Revenue | 4.97 M | ||||
| Gross Profit | (40.4 M) | ||||
| EBITDA | (51.63 M) | ||||
| Net Income | (54.04 M) | ||||
| Cash And Equivalents | 267.13 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 2.44 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.37 X | ||||
| Book Value Per Share | 2.55 X | ||||
| Cash Flow From Operations | (59.25 M) | ||||
| Earnings Per Share | (1.67) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 158 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 133.14 M | ||||
| Total Asset | 158.53 M | ||||
| Retained Earnings | (246.29 M) | ||||
| Working Capital | 143.5 M | ||||
| Net Asset | 158.53 M |
About Molecular Partners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Partners AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Partners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Partners AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Molecular Stock Analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.